The acute repetitive seizure is a condition that occurs in patients
with drug-refractory epilepsy. It is also known as cluster seizure,
seizure flurry, breakthrough seizure, seizure cluster, serial seizure,
or prolonged seizure. The acute repetitive seizure is characterized by
the occurrence of seizures within short intervals, which could be within
hours or even a few minutes. The frequency of occurrence of these
seizures depends upon the type of epilepsy such as mesial temporal lobe
epilepsy and the patient characteristics. Three catamenial seizures
occur within two premenstrual days in women with mesial temporal lobe
epilepsy. Rectal gels and nasal sprays are used for the management of
acute repetitive seizures.
Increase in the number of clinical trials, a rise in emphasis on the
launch of new therapies, and the surge in demand for nasal sprays for
the treatment of epilepsy are the major factors projected to drive the
global acute repetitive seizures market. Additionally, an increase in
the number of regulatory approvals and promising drugs in the pipeline
is anticipated to fuel the growth of the acute repetitive seizures
market during the forecast period. For instance, in April 2018, UCB S.A.
announced that the Food and Drug Administration (FDA) accepted a new
drug application (NDA) for Nayzilam (midazolam) nasal spray indicated
for the treatment of seizures such as seizure clusters and acute
repetitive seizures. This could result in the approval of the drug in
early 2019, making it the first ever medication approved by the FDA in
more than 17 years.
The global acute repetitive seizures market can be segmented based on
product, route of administration, distribution channel, and region. In
terms of product, the acute repetitive seizures market can be divided
into USL-261, VALTOCO, AZ-002, Diastat rectal gel, and others. Based on
the route of administration, the global acute repetitive seizures market
can be classified into nasal, oral, rectal, and others. The nasal
segment is anticipated to expand at the fastest CAGR during the forecast
period due to shifting from rectal to nasal route of administration and
increase in the number of patients preferring nasal sprays due to ease
of administration. In terms of the distribution channel, the acute
repetitive seizures market can be categorized into hospital pharmacies,
retail pharmacies, and online pharmacies. The retail pharmacies segment
is expected to expand at the fastest CAGR owing to increase in the
availability of medications for serious disease conditions at these
pharmacies, ease of access, an increase in the chain of retail
pharmacies supplying medications for acute repetitive seizures.
The global acute repetitive seizures market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest market share during the forecast period. The acute repetitive seizures market in the region is driven by an increase in the number of pharmaceutical companies engaged in new drug development and rise in prevalence of epileptic seizures. In September 2018, Neurelis, Inc., a pharmaceutical company based in San Diego, the U.S., submitted a New Drug Application (NDA) with the FDA for VALTOCO as a treatment for epilepsy patients with acute repetitive seizures. The acute repetitive seizures market in Europe is anticipated to grow at a rapid pace from 2018 to 2026 due to rise in investment in research and development in the field of neurology, increase in funds offered by the government, and surge in demand for medications for epilepsy. The market in the Asia Pacific is expected to expand at the fastest CAGR during the forecast period driven by rising in awareness about the treatment of neurological disorders and increase in demand for new drug formulations for treating serious conditions in neurology.
Key players operating in the global acute repetitive seizures market are UCB S.A., Neurelis, Inc., Alexza Pharmaceuticals, and Valeant Pharmaceuticals North America LLC.
The global acute repetitive seizures market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for the largest market share during the forecast period. The acute repetitive seizures market in the region is driven by an increase in the number of pharmaceutical companies engaged in new drug development and rise in prevalence of epileptic seizures. In September 2018, Neurelis, Inc., a pharmaceutical company based in San Diego, the U.S., submitted a New Drug Application (NDA) with the FDA for VALTOCO as a treatment for epilepsy patients with acute repetitive seizures. The acute repetitive seizures market in Europe is anticipated to grow at a rapid pace from 2018 to 2026 due to rise in investment in research and development in the field of neurology, increase in funds offered by the government, and surge in demand for medications for epilepsy. The market in the Asia Pacific is expected to expand at the fastest CAGR during the forecast period driven by rising in awareness about the treatment of neurological disorders and increase in demand for new drug formulations for treating serious conditions in neurology.
Key players operating in the global acute repetitive seizures market are UCB S.A., Neurelis, Inc., Alexza Pharmaceuticals, and Valeant Pharmaceuticals North America LLC.
No comments:
Post a Comment